Catalyst Wire Dossier Catalyst Wire Dossier

Nezastomig

REGN5678 · Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nezastomig, covering 2025-11-06 to 2025-11-06. Get the full timeline:

Most recent: Clinical Trial Update: A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors [Phase 1, Phase 2]

See pricing